Search - tctmd.com

Displaying 541 - 560 of 809

Sort: Relevancy | Date

Presentation

Cost-Effectiveness of PFO Closure vs Medical Therapy for Cryptogenic Stroke

Presenter: Christopher A. Pickett

September 30, 2014

Presentation TCT 2014

TAVR Controversies: Strokes and Paravalvular Regurgitation Will New TAVR Systems or Accessory Devices Make a Difference?

Presenter: Matthew G. Hillebrenner, Michael J. Mack, Daniel I. Simon, Samir R. Kapadia

September 16, 2014

Presentation TCT 2014

TCT 176: Comparison of Imputed Placebo Versus Observed Ischemic Stroke Rates in the Watchman Trials Shows a Significant Reduction in Risk

Presenter: John M. Lasala, Stuart J. Pocock, George Hanzel, MD

September 16, 2014

Presentation TCT 2014

Cost-effectiveness Analysis Of Left Atrial Appendage Occlusion Device Compared With 7 Oral Anticoagulants For Stroke Prevention In Atrial Fibrillation

Presenter: Vivian Lee

September 16, 2014

Presentation TCT 2014

Comparison of Imputed Placebo Versus Observed Ischemic Stroke Rates in the Watchman Trials Represents a Significant Reduction in Risk

Presenter: George Hanzel

September 16, 2014

Presentation TCT 2014

The Role of Right Sided Hemodynamic Parameters as Predictors of 30 Day Outcome After Transcatheter Aortic Valve Replacement: The Impact of Right Ventricular Stroke Work Index

Presenter: Rajiv Tayal

September 16, 2014

Presentation TCT 2014

TCT 170: Cost-effectiveness Analysis of a Left Atrial Appendage Occlusion Device Compared with 7 Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation

Presenter: Saibal Kar, Bushra S Rana, Jai-Wun Park, Vivian Lee

September 15, 2014

Presentation TCT 2014

Featured Presentation: Vorapaxar Safety and Efficacy Results in the FDA-Approved, Stroke-Free MI and PAD Populations

Presenter: Ori Ben-Yehuda, Matthew T. Roe, David J. Moliterno, Marc Bonaca

September 15, 2014

Presentation TCT 2014

Old and New Anticoagulants for Stroke Prevention: Benefits and Risks

Presenter: Josep Rodés-Cabau, Brian K. Whisenant, David Hildick-Smith, Jonathan L. Halperin

September 15, 2014

Presentation TCT 2014

Stroke, Bleeding, and Risk Scores in Atrial Fibrillation

Presenter: Josep Rodés-Cabau, Brian K. Whisenant, David Hildick-Smith, Stefan C. Bertog

September 15, 2014

Presentation TCT 2014

Bleeding and Stroke Risk Assessment in Atrial Fibrillation: Choosing between Warfarin, NOACS, Antiplatelets, or Nothing?

Presenter: Matthew J. Price, Michael D. Ezekowitz

September 15, 2014

Presentation TCT 2014

Against the Proposal!

Presenter: Tudor G. Jovin

September 14, 2014

Presentation TCT 2014

For the Proposal!

Presenter: Philip M. Meyers

September 14, 2014

Presentation TCT 2014

Can LAA Closure Become the New Standard for Stroke Prevention?

Presenter: Hilary Nierenberg, Julie Logan, Saibal Kar

September 14, 2014

Presentation TCT 2014

Atrial Fibrillation: Stratifying Stroke Risk and Determining Anticoagulant Therapy

Presenter: Hilary Nierenberg, Julie Logan, Asma Hussaini

September 14, 2014

Presentation TCT 2014

TCT 685: Costs of Periprocedural Complications Among Patients Treated with a Self-Expanding Transcatheter Aortic Valve Prosthesis: Results from the CoreValve US Pivotal Extreme-Risk Study

Presenter: Samir R. Kapadia, Patrick T. O'Gara, G. Michael Deeb, Suzanne Baron

September 14, 2014

Presentation TCT 2014

TCT 664: Cardiac Magnetic Resonance Versus Transthoracic Echocardiography for the Assessment and Quantification of Aortic Regurgitation in Patients Undergoing Transcatheter Aortic Valve Implantation

Presenter: Samir R. Kapadia, Patrick T. O'Gara, G. Michael Deeb, Henrique B. Ribeiro

September 14, 2014

Presentation TCT 2014

Paravalvular Regurgitation After TAVR II: Will New TAVR Systems Eliminate the Problem?

Presenter: Samir R. Kapadia, Patrick T. O'Gara, G. Michael Deeb, Ian T. Meredith

September 14, 2014

Presentation TCT 2014

Paravalvular Regurgitation After TAVR I: Incidence, Etiologies, Diagnostic Considerations, Clinical Impact, and Treatment Alternatives

Presenter: Samir R. Kapadia, Patrick T. O'Gara, G. Michael Deeb, Susheel Kodali

September 14, 2014

Presentation TCT 2014

Neurocognitive Functional Assessment After TAVR: Methodologies and Clinical Importance

Presenter: Samir R. Kapadia, Patrick T. O'Gara, G. Michael Deeb, Ronald M. Lazar

September 14, 2014

Advertisement

Cost-Effectiveness of PFO Closure vs Medical Therapy for Cryptogenic Stroke

TAVR Controversies: Strokes and Paravalvular Regurgitation Will New TAVR Systems or Accessory Devices Make a Difference?

TCT 176: Comparison of Imputed Placebo Versus Observed Ischemic Stroke Rates in the Watchman Trials Shows a Significant Reduction in Risk

Cost-effectiveness Analysis Of Left Atrial Appendage Occlusion Device Compared With 7 Oral Anticoagulants For Stroke Prevention In Atrial Fibrillation

Comparison of Imputed Placebo Versus Observed Ischemic Stroke Rates in the Watchman Trials Represents a Significant Reduction in Risk

The Role of Right Sided Hemodynamic Parameters as Predictors of 30 Day Outcome After Transcatheter Aortic Valve Replacement: The Impact of Right Ventricular Stroke Work Index

TCT 170: Cost-effectiveness Analysis of a Left Atrial Appendage Occlusion Device Compared with 7 Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation

Featured Presentation: Vorapaxar Safety and Efficacy Results in the FDA-Approved, Stroke-Free MI and PAD Populations

Old and New Anticoagulants for Stroke Prevention: Benefits and Risks

Stroke, Bleeding, and Risk Scores in Atrial Fibrillation

Bleeding and Stroke Risk Assessment in Atrial Fibrillation: Choosing between Warfarin, NOACS, Antiplatelets, or Nothing?

Against the Proposal!

For the Proposal!

Can LAA Closure Become the New Standard for Stroke Prevention?

Atrial Fibrillation: Stratifying Stroke Risk and Determining Anticoagulant Therapy

TCT 685: Costs of Periprocedural Complications Among Patients Treated with a Self-Expanding Transcatheter Aortic Valve Prosthesis: Results from the CoreValve US Pivotal Extreme-Risk Study

TCT 664: Cardiac Magnetic Resonance Versus Transthoracic Echocardiography for the Assessment and Quantification of Aortic Regurgitation in Patients Undergoing Transcatheter Aortic Valve Implantation

Paravalvular Regurgitation After TAVR II: Will New TAVR Systems Eliminate the Problem?

Paravalvular Regurgitation After TAVR I: Incidence, Etiologies, Diagnostic Considerations, Clinical Impact, and Treatment Alternatives

Neurocognitive Functional Assessment After TAVR: Methodologies and Clinical Importance

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content